MedX Health Corp. Announces Extension of Private Placement

MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX) announces that it
has extended, to April 30, 2014, the date for closing of a further tranche of
the private placement of units ("Unit(s)"), in respect of which the first
tranche, which raised $565,000, was closed on March 19, 2014. As previously,
Trapeze Capital Corp., is acting as lead agent (the "Agent"). Each Unit
comprises one common share and one share purchase warrant (a "Warrant") at $0.10
per Unit. Each Warrant entitles the holder to purchase one additional common
share during the period expiring two years following closing at $0.20 per share.
MedX will pay the Agent a cash commission of 8% of cash raised, subject to a
reduced rate in respect of subscribers on the "President's List", and will issue
broker warrants to the Agent equal in number to 8% of the Units issued. Each
broker warrant will be exercisable at $0.10 to acquire a unit comprising one
common share and one share purchase warrant exercisable to acquire an additional
common share from treasury at an exercise price of $0.20; the broker warrants
and the share purchase warrants underlying the broker warrants will expire two
years after the closing of the placement. Any shares comprised in the Units and
the Warrants and any shares issued on exercise of the Warrants or the broker
warrants or the share purchase warrants underlying the units in the broker
warrants will be restricted from trading for a period of four months and one day
from the date of closing of the issue.


MedX currently has 65,394,657 shares outstanding.

About MedX

MedX is headquartered in Mississauga, Ontario (Toronto), and is a global leader
in the design, manufacturing and distribution of quality low level laser and
light therapy technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine, providing
patients with drug free and non-invasive treatment of tissue damage and pain.
MedX laser and light products are FDA approved, Health Canada cleared, and CE
Mark approved for use in North America as well as the European Union. MedX's
products include SIMSYS(TM) and MoleMate(TM), which are approved by Health
Canada, and available to Canadian physicians and dermatologists, are FDA
approved for use in the USA and are currently under review for CE approval for
use in Europe, the UK, and Australia, as an optical biopsy that uses patented
technology featuring a hand-held scanner device designed for clinical use that
utilizes light to view beneath suspicious moles or lesions in a pain free,
non-invasive manner, creating images in real-time for physicians and
dermatologists to evaluate all types of moles or lesions within seconds. For
more information log onto: www.simsys-molemate.com. For a complete profile of
MedX and its products visit www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This
press release contains certain forward-looking statements within the meaning of
applicable Canadian securities legislation. These forward-looking statements
involve certain risks and uncertainties that could cause actual results to
differ, including, without limitation, the company's limited operating history
and history of losses, the inability to successfully obtain further funding, the
inability to raise capital on terms acceptable to the company, the inability to
compete effectively in the marketplace, the inability to complete the proposed
acquisition and such other risks that could cause the actual results to differ
materially from those contained in the company's projections or forward-looking
statements. All forward looking statements in this press release are based on
information available to the company as of the date hereof, and the company
undertakes no obligation to update forward-looking statements to reflect events
or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
MedX Health Corp.
Robert von der Porten
President and CEO
905 670 4428
investor@medxhealth.com
www.medxhealth.com
Medx Health (TSXV:MDX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024